Associate Professor of Medicine
Indiana University, United States
Dr. Fabiana Perna is a physician-scientist focused on the pathogenesis and treatment of hematological malignancies.
She completed clinical training as hematologist in Italy. In 2008, she joined the laboratory of Dr. Stephen D. Nimer at Memorial Sloan Kettering Cancer Center, where she contributed investigating the role of several recurring epigenetic mutations in hematopoiesis, while completing a PhD program. These studies were published on several high-impact scientific journals and, she was awarded an American Italian Cancer Foundation fellowship, the clinical fellowship of MSKCC, the Translational Research Training in Hematology (TRTH) and a competitive American Society of Hematology (ASH) Scholar Award. In 2012, she joined the laboratory of Dr. Michel Sadelain, at MSKCC, a pioneer of Chimeric Antigen Receptor (CAR) T-cell technology. Given her previous expertise in myeloid malignancies, she developed a compelling platform, which integrates proteomics and transcriptomics to unbiasedly identify CAR T-cell targets for Acute Myeloid Leukemia (Perna F et al., Cancer Cell 2017). She was awarded a Technology Development Fund and co-invented multiple patents.
In 2019 she joined Indiana University as an independent investigator with her own lab and large start-up funds. Here, she obtained board eligibility and received research grants from the Leukemia Research Foundation, NIH, IU, and multiple biotech/pharma companies to develop novel CAR T-cells and launch an investigator-initiated phase-I clinical trial. She has published over 40 manuscripts in high-impact scientific journals and is an active member of the ASH. The Perna lab developed novel methodologies identifying surface targets for developing novel cancer immunotherapies.
Disclosure information not submitted.
Target Discovery Strategies for Developing Novel Cancer Immunotherapies
Wednesday, June 21, 2023
1:00 PM - 1:25 PM
